Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2024-03-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于向下修正泰林转债转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the downward adjustment of the conversion price of its convertible bonds ("Tailin Convertible Bonds"). It includes details about the bond issuance, previous adjustments to the conversion price, the regulatory basis for the adjustment, the approval process including board and shareholder meetings, and the final adjusted conversion price effective date. The document is a formal disclosure of a capital structure change related to convertible bonds, specifically the adjustment of the conversion price, which affects the terms of the convertible bonds and potentially the company's capital structure. It is not a full financial report, earnings release, or management discussion, but a specific update on financing terms. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3115 characters, which is sufficient for a detailed announcement but not a full report. No indication that this is a report publication announcement or regulatory filing fallback. Hence, the classification is CAP with high confidence.
2024-03-11 Chinese
关于召开2024年第一次临时股东大会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the 2024 first extraordinary general meeting (临时股东大会) of Zhejiang Tailin Biotechnology Co., Ltd. It includes information about the meeting time, location, voting procedures (both onsite and online), agenda items, and related attachments such as proxy forms and registration forms. The document does not contain financial statements or results, nor is it a transcript or presentation. It is not a report publication announcement since it contains substantive details about the meeting itself. The content fits the category of a formal notice or announcement related to a shareholders' meeting, specifically an Extraordinary General Meeting (EGM). According to the filing definitions, announcements about shareholder meetings and their details fall under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). However, since this document is a notice of the meeting itself and not the voting results, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting and voting procedures, not the results or the meeting materials themselves. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-03-07 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司持续督导之2023年度培训情况报告
Regulatory Filings Classification · 85% confidence The document is a report from a sponsoring securities company about a 2023 annual training session conducted for a listed company as part of continuous supervision. It details the training content, participants, and outcomes related to regulatory compliance and company operations. The document is short (982 characters) and focuses on a specific training event rather than financial results, management changes, or regulatory filings. It does not contain financial statements or earnings data, nor is it an announcement of voting results or capital changes. It is a specialized report related to regulatory compliance training, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a general regulatory filing or announcement but a specific report on a training event. Given the available categories, none perfectly match this type of training report. The closest fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not neatly fit into other categories.
2024-03-06 Chinese
关于全资子公司取得不动产权证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a property ownership certificate by a wholly-owned subsidiary. It details the transaction overview, the certificate specifics, and the impact on the company. The document is short (1109 characters) and does not contain financial statements or detailed financial data. It is an announcement of a corporate event related to asset acquisition, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a corporate asset acquisition event.
2024-03-05 Chinese
内幕信息知情人登记管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system for insider information registration and confidentiality at Zhejiang Tailin Biotechnology Co., Ltd. It outlines the procedures, responsibilities, and legal basis for managing insider information and insider personnel records. It includes definitions, scope, registration, confidentiality, and responsibility sections, as well as attachments for insider personnel records and major event progress memoranda. There are no financial statements, earnings data, or investor presentations. It is a governance-related document focused on internal control and compliance with securities laws and regulations. Therefore, it fits best under Governance Information (CGR). The document length (6755 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive governance policy document.
2024-02-19 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '浙江泰林生物技术股份有限公司 对外投资管理制度' which translates to 'Zhejiang Tailin Biotechnology Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the company's procedures, principles, decision-making authority, execution, supervision, disclosure, financial management, and responsibilities related to external investments. It references relevant laws and regulations but does not contain financial statements, earnings data, or audit results. It is not an announcement or a report of financial results, nor is it a regulatory filing or certification. It is a governance-related document detailing internal rules and governance practices regarding investment management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3834 characters, which is substantive and not a brief announcement or notice.
2024-02-19 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.